ST Pharm promotes oligonucleotide CDMO business at CPHI Worldwide 2026

ST Pharm participated in CPHI Worldwide 2026, held in Milan, Italy, from October 6 to 8, to promote its oligonucleotide Contract Development and Manufacturing Organization (CDMO) capabilities. The company utilized the event to conduct business meetings with global pharmaceutical and biotech firms, aiming to strengthen existing partnerships and secure new projects.

To meet the rising global demand for oligonucleotide CDMO services, ST Pharm has begun full-scale operations of its second oligonucleotide production facility, which was completed last year. This facility features production lines ranging from small to large scale, allowing the company to support clients from early clinical stages through to commercialization. Additionally, the company is engaging with customers in the small molecule active pharmaceutical ingredient (API) sector to discuss ongoing projects and potential business expansions.